NASDAQ · PALI
Palisade Bio, Inc.
$1.19$0.00 (0.0%)
Palisade Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.39% below the high.
Loading market information…
NASDAQ · PULM · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Pulmatrix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.64% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Pulmatrix, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$2.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Pulmatrix, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:21 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.19$0.00 (0.0%)
Palisade Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.39% below the high.
$0.77-$0.03 (-3.15%)
Leap Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.5% below the high.
$0.56+$0.02 (+4.07%)
Citius Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.45% below the high.
$0.80-$0.02 (-2.22%)
Hoth Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.29% below the high.
$0.68+$0.00 (+0.22%)
Dare Bioscience, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.97% below the high.
$0.93-$0.04 (-3.99%)
FibroBiologics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 90.33% below the high.
$1.75-$0.03 (-1.69%)
Longeveron Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.77% below the high.
$0.55+$0.09 (+20.81%)
Curis, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.28% below the high.
